| Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017 C Hiemke, N Bergemann, HW Clement, A Conca, J Deckert, K Domschke, ... Pharmacopsychiatry 51 (01/02), 9-62, 2018 | 1400 | 2018 |
| An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels J De Leon, G Schoretsanitis, RL Smith, E Molden, A Solismaa, N Seppälä, ... Pharmacopsychiatry 55 (02), 73-86, 2022 | 193 | 2022 |
| A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology J de Leon, CJ Ruan, G Schoretsanitis, C De las Cuevas Psychotherapy and psychosomatics 89 (4), 200-214, 2020 | 142 | 2020 |
| TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians G Schoretsanitis, M Paulzen, S Unterecker, M Schwarz, A Conca, ... The world journal of biological psychiatry 19 (3), 162-174, 2018 | 126 | 2018 |
| Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations G Ostuzzi, D Papola, C Gastaldon, G Schoretsanitis, F Bertolini, ... BMC medicine 18, 1-14, 2020 | 116 | 2020 |
| Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic ¡K G Schoretsanitis, JM Kane, CU Correll, SR Marder, L Citrome, ... The journal of clinical psychiatry 81 (3), 3649, 2020 | 113 | 2020 |
| Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system C Gastaldon, E Raschi, JM Kane, C Barbui, G Schoretsanitis Psychotherapy and psychosomatics 90 (1), 41-48, 2020 | 101 | 2020 |
| A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients G Schoretsanitis, JM Kane, CJ Ruan, E Spina, C Hiemke, J de Leon Expert review of clinical pharmacology 12 (7), 603-621, 2019 | 95 | 2019 |
| Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis JM Rubio, G Schoretsanitis, M John, J Tiihonen, H Taipale, D Guinart, ... The Lancet Psychiatry 7 (9), 749-761, 2020 | 90 | 2020 |
| Do Asian patients require only half of the clozapine dose prescribed for Caucasians? A critical overview J Leon, AP Rajkumar, AR Kaithi, G Schoretsanitis, JM Kane, CY Wang, ... Indian Journal of Psychological Medicine 42 (1), 4-10, 2020 | 82 | 2020 |
| A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone G Schoretsanitis, E Spina, C Hiemke, J de Leon Expert review of clinical pharmacology 10 (9), 965-981, 2017 | 79 | 2017 |
| Risk factors of postpartum depression and depressive symptoms: umbrella review of current evidence from systematic reviews and meta-analyses of observational studies C Gastaldon, M Solmi, CU Correll, C Barbui, G Schoretsanitis The British Journal of Psychiatry 221 (4), 591-602, 2022 | 62 | 2022 |
| Sertraline in pregnancy¡VTherapeutic drug monitoring in maternal blood, amniotic fluid and cord blood M Paulzen, TW Goecke, E Stickeler, G Gründer, G Schoretsanitis Journal of affective disorders 212, 1-6, 2017 | 56 | 2017 |
| Antidepressants in breast milk; comparative analysis of excretion ratios G Schoretsanitis, M Augustin, H Saßmannshausen, C Franz, G Gründer, ... Archives of Women's Mental Health 22, 383-390, 2019 | 53 | 2019 |
| A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone G Schoretsanitis, E Spina, C Hiemke, J de Leon Expert Review of Clinical Pharmacology 11 (12), 1237-1253, 2018 | 52 | 2018 |
| An update on the complex relationship between clozapine and pneumonia G Schoretsanitis, CJ Ruan, C Rohde, H Verdoux, C De Las Cuevas, ... Expert Review of Clinical Pharmacology 14 (2), 145-149, 2021 | 50 | 2021 |
| Keep at bay!¡VAbnormal personal space regulation as marker of paranoia in schizophrenia G Schoretsanitis, A Kutynia, K Stegmayer, W Strik, S Walther European Psychiatry 31, 1-7, 2016 | 46 | 2016 |
| Using therapeutic drug monitoring to personalize clozapine dosing in Asians J de Leon, G Schoretsanitis, JM Kane, CJ Ruan Asia‐Pacific Psychiatry 12 (2), e12384, 2020 | 45 | 2020 |
| The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis G Schoretsanitis, O Spigset, JC Stingl, KM Deligiannidis, M Paulzen, ... Expert opinion on drug metabolism & toxicology 16 (5), 431-440, 2020 | 43 | 2020 |
| Inhibitory repetitive transcranial magnetic stimulation to treat psychomotor slowing: a transdiagnostic, mechanism-based randomized double-blind controlled trial S Walther, D Alexaki, G Schoretsanitis, F Weiss, I Vladimirova, ... Schizophrenia Bulletin Open 1 (1), sgaa020, 2020 | 40 | 2020 |
